TXMD Stock Analysis: Buy, Sell, or Hold?
TXMD - TherapeuticsMD, Inc.
$2.00
0.00 (0.00%)
▲
5d:
-12.28%
30d:
-5.21%
90d:
-13.42%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When TXMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TXMD is down 12.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TXMD is down 12.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TXMD is currently trading at $2.00, which is considered fair relative to its 30-day fair value range of $1.93 to $2.18.
Technical Outlook: Technically, TXMD is in a downtrend. Immediate support is located at $1.80, while resistance sits at $2.17.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $5.00 (+150.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TXMD is in a downtrend. Immediate support is located at $1.80, while resistance sits at $2.17.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $5.00 (+150.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.93 -
$2.18
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 150.0% below Wall St target ($5.00)
- WARNING: Recommendation downgraded due to -12.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.93 -
$2.18
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.40
(20.0%)
Support & Resistance Levels
Support Level
$1.80
Resistance Level
$2.17
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.33
Wall Street Target
$5.00
(+150.0%)
Revenue Growth (YoY)
84.2%
Profit Margin
5.3%
Share & Embed Analysis
Last updated: June 24, 2026 3:50 AM ET
Data refreshes hourly during market hours. Next update: 4:50 AM
Data refreshes hourly during market hours. Next update: 4:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TXMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
